| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5628 | Zinc17043486 | Novel CDK6 inhibitor |
|
| DCC5629 | Zinc17167211 | Potent and selective agonist of peroxisome proliferator activated receptors-α (PPAR-α) |
|
| DCC5630 | Zinc20531199 | Novel EGFR triple mutant T790M/C797S allosteric inhibitor |
|
| DCC5631 | Zinc27905174 | Novel GDNF Family Receptor Agonist |
|
| DCC5632 | Zinc32540717 | Potent Ebolavirus (EBOV) Inhibitor |
|
| DCC5633 | Zinc36617540 | Novel Nef Protein Inhibitor; Anti-HIV |
|
| DCC5634 | Zinc4085554 | Novel blocker of AKT1-FAK interaction, reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620 colon cancer cells without affecting basal FAK phosphorylation |
|
| DCC5635 | Zinc50166190 | Novel Zika virus RNA polymerase inhibitor |
|
| DCC5636 | Zinc63908257 | Novel CtpF inhibitor, inhibiting Ca -dependent ATPase activity in Mtb membrane vesicles |
|
| DCC5637 | Zinc64700951 | Novel gp120 of HIV-1 Antagonist |
|
| DCC5638 | Zinc65022200 | Novel potent and specific inhibitor of the UNC119-Src interaction, binding to UNC119 in cells, and inducing redistribution of Src to endomembranes and reduction of activating Src autophosphorylation on Y419 |
|
| DCC5639 | Zinc69811181 | Novel ASCT2 inhibitor |
|
| DCC5640 | Zinpyr-1 | Cell-permeable fluorometric zinc sensor |
|
| DCC5641 | Zk187638 | Non-competitive AMPA receptor antagonist |
|
| DCC5642 | Zk230211 | Type III progesterone receptor antagonist with enhanced antiproliferative properties |
|
| DCC5643 | Zk-304709 | Novel oral multitarget tumour growth inhibitor |
|
| DCC5644 | Zk-806450 | Novel potent inhibitor of factor Xa (FXa) |
|
| DCC5645 | Zl006-05 | Novel dual mordulator of nNOS-PSD-95 interaction and GABA A receptor |
|
| DCC5646 | Zl0513 | Novel potent and selective BRD4 bromodomain 1 (BD1) inhibitor |
|
| DCC5647 | Zl0516 | Novel potent and selective BRD4 bromodomain 1 (BD1) inhibitor |
|
| DCC5648 | Zl3138 | Novel β-catenin/B-cell lymphoma 9 (BCL9) inhibitor, disrupting the β-catenin/BCL9 protein-protein interaction (PPI) with a Ki of 0.96 μM and without affecting the β-catenin/E-cadherin interaction in living cells, displaying good selectivity for β-catenin/ |
|
| DCC5649 | Zld10a | Novel potent and highly selective inhibitor of wild-type and mutant versions of EZH2 |
|
| DCC5650 | Zm-181037 | ATP-sensitive potassium channel-blocker; Eukalemic diuretic |
|
| DCC5651 | zm-189154 | Non-steroidal pure antioestrogen |
|
| DCC5652 | zm-230487 | 5-Lipoxygenase (5-LO) inhibitor |
|
| DCC5653 | Zm-244085 | K-Channel opener (PCO) activating predominantly KATP channels in vitro to relax bladder detrusors |
|
| DCC5654 | zm-253270 | Selective nonpeptide, NK-2 receptor (NK-2R) antagonist |
|
| DCC5655 | Zm-260384 | Potassium channel opener |
|
| DCC5656 | Zm39923 Hydrochloride | Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3) |
|
| DCC5657 | Zn-htsm | Novel antidiabetic agent for the treatment of type 2 diabetes mellitus (DM) |
|
